Patents Assigned to AstraZeneca
  • HIGHLY SOLUBLE LEPTINS
    Publication number: 20130203661
    Abstract: The disclosure provides chimeric polypeptides and nucleic acid molecules encoding chimeric polypeptides. Also provided are pharmaceutical compositions and methods of treatment for diseases and disorders including lipodystrophy, dyslipidemia, hyperlipidemia, overweight, obesity, hypothalamic amenorrhea, Alzheimer's disease, leptin deficiency, fatty liver disease or diabetes (including type I and type II). Additional diseases and disorders which can be treated by the compounds and methods described herein include nonalcoholic steatohepatitis (NASH) and nonalcoholic fatty liver disease (NAFLD), metabolic syndrome X and Huntington's Disease.
    Type: Application
    Filed: March 28, 2013
    Publication date: August 8, 2013
    Applicants: ASTRAZENECA PHARMACEUTICALS LP, Amylin Pharmaceuticals, LLC
    Inventors: Amylin Pharmaceuticals, LLC, ASTRAZENECA PHARMACEUTICALS LP
  • CHEMICAL COMPOUNDS - 643
    Publication number: 20130203714
    Abstract: The invention concerns bicyclic compounds of Formula I wherein R1, R2, L1, L2, J, Y, k, n, p and r are as defined in the description. The present invention also relates to processes for the preparation of such compounds, pharmaceutical compositions containing them and their use in the treatment of androgen-receptor associated conditions, particularly prostate cancer.
    Type: Application
    Filed: August 1, 2012
    Publication date: August 8, 2013
    Applicant: ASTRAZENECA R&D
    Inventors: Robert Hugh Bradbury, Gregory Richard Carr, Alfred Arthur Rabow, Srinivasa Rao Korupoju, Harikrishna Tumma
  • Process for Making a Metabotropic Glutamate Receptor Positive Allosteric Modulator - 874
    Publication number: 20130203995
    Abstract: Processes for making 7-methyl-5-(3piperazin-1-ylmethyl-[1,2,4]oxadiazol-5-yl)-2-(4-trifluoromethoxybenzyl)-2,3-dihydroisoindol-1-one
    Type: Application
    Filed: January 4, 2011
    Publication date: August 8, 2013
    Applicant: ASTRAZENECA AB
    Inventors: Alistair Boyd, Mark Richard Fielding, James Gair Ford, Lianne Frodsham, Michael D. Golden, Kevin William Leslie, Ben Mckeever-Abbas, Paula Tomlin
  • Pyrimidine Sulphonamide Derivatives as Chemokine Receptor Modulators
    Publication number: 20130203991
    Abstract: A compound of formula (I), or a pharmaceutically acceptable salt, solvate or in vivo hydrolysable ester thereof and pharmaceutical compositions comprising these, all for use in the treatment of chemokine mediated diseases and disorders.
    Type: Application
    Filed: March 15, 2013
    Publication date: August 8, 2013
    Applicant: ASTRAZENECA R&D ALDERLY PARK
    Inventor: AstraZeneca R&D Alderly Park
  • INHALER CAP STRAP
    Publication number: 20130199525
    Abstract: An inhaler for dispensing doses of medicament from a container under user activation said inhaling which comprises a body which includes a mouthpiece through which the medicament is dispensed and a cap which can be place in a position to substantially occlude the mouthpiece. The cap is attached to said body by a strap which pivots from said body, said cap being arranged to slide on the strap such that the cap must translate away from the mouthpiece prior to the pivoting of the strap.
    Type: Application
    Filed: January 25, 2013
    Publication date: August 8, 2013
    Applicant: AstraZeneca AB
    Inventor: AstraZeneca AB
  • Use of exendins and exendin agonists and GLP-1 receptor agonists for altering the concentration of fibrinogen
    Patent number: 8501693
    Abstract: The present invention relates to altering the concentration of fibrinogen, specifically, for example, by decreasing fibrinogen concentration. The present invention also relates to methods for improving the cardiovascular risk profile of a subject by decreasing fibrinogen concentration.
    Type: Grant
    Filed: August 6, 2007
    Date of Patent: August 6, 2013
    Assignees: Amylin Pharmaceuticals, LLC, Astrazeneca Pharmaceuticals LP
    Inventors: Dennis Kim, Michael Trautmann
  • Benzimidazole compounds
    Patent number: 8501956
    Abstract: Provided are compounds having Formula VIIIa-1: wherein Z, X5, R2, R2a and R10 are as defined herein. Compounds of Formula VIIIa-1 can be used to prepare heterocyclic derivatives such as benzimidazole derivatives.
    Type: Grant
    Filed: September 9, 2011
    Date of Patent: August 6, 2013
    Assignees: Array BioPharma Inc., AstraZeneca SB
    Inventors: John Demattei, Sagar Shakya, Anthony D. Piscopio, Bruno P. Hache, Matthew Charles Evans, James Gair Ford, Simon Mark Pointon, Koen Peeters, Timothy John Lilley, John Leonard
  • 2-pyridone derivatives as neutrophil elastase inhibitors and their use
    Patent number: 8501784
    Abstract: There are provided novel compounds of formula (I), wherein R1, R2, R4, G1, G2, L, Y and n are as defined in the Specification and optical isomers, racemates and tautomers thereof, and pharmaceutically acceptable salts thereof; together with processes for their preparation, compositions containing them and their use in therapy. The compounds are inhibitors of neutrophil elastase.
    Type: Grant
    Filed: October 14, 2011
    Date of Patent: August 6, 2013
    Assignee: Astrazeneca AB
    Inventors: Marjana Andersson, Peter Hansen, Hans Lonn, Antonios Nikitidis, Petter Sjölin
  • GIP ANALOG AND HYBRID POLYPEPTIDES WITH SELECTABLE PROPERTIES
    Publication number: 20130196913
    Abstract: The present invention relates generally to novel GIP analogs and GIP hybrid polypeptides with selectable properties, useful as agents for the treatment and prevention of metabolic diseases and disorders, for example those which can be alleviated by control plasma glucose levels, insulin levels, and/or insulin secretion, positive inotropic effects, reduction of catabolic effects, slowing of gastric emptying. Such conditions and disorders include, but are not limited to, hypertension, dyslipidemia, cardiovascular disease, eating disorders, critical care, insulin-resistance, obesity, and diabetes mellitus of any kind, including type 1, type 2, and gestational diabetes.
    Type: Application
    Filed: March 25, 2013
    Publication date: August 1, 2013
    Applicants: AstraZeneca Pharmaceuticals LP, Amylin Pharmaceuticals, LLC
    Inventors: Amylin Pharmaceuticals, LLC, AstraZeneca Pharmaceuticals LP
  • PHARMACEUTICAL COMPOSITION 271
    Publication number: 20130195971
    Abstract: The invention concerns pharmaceutical compositions containing a hydrogen sulphate salt of 6-(4-bromo-2-chloro-phenylamino)-7-fluoro-3-methyl-3H-benzoimidazole-5-carboxylic acid (2-hydroxy-ethoxy)-amide and solvates, crystalline forms and amorphous forms thereof, to the use of said compositions as a medicament; and to processes for the preparation of said compositions.
    Type: Application
    Filed: January 23, 2013
    Publication date: August 1, 2013
    Applicants: Array BioPharma, Inc., AstraZeneca AB
    Inventors: AstraZeneca AB, Array BioPharma, Inc.
  • GABR-A2 DIAGNOSTIC
    Publication number: 20130197041
    Abstract: The present invention provides a method of selection of a patient, who is a candidate for treatment with an NMDA antagonist drug, such as (S)-1-phenyl-2-(pyridin-2-yl)ethanamine or ketamine, whereby to predict an increased or decreased likelihood of response to the NMDA antagonist. The invention provides a method for determining the sequence of GABR-A2 at any of four single nucleotide polymorphism (SNP) sites known as rs3756007, rs11503016, rs17537359 or rs1372472. The method also provides ARMS primers optimised for determining the sequence at these GABR-A2 SNPs and diagnostic kits comprising suitable primers or probes for determining the particular SNPs.
    Type: Application
    Filed: December 14, 2012
    Publication date: August 1, 2013
    Applicant: ASTRAZENECA AB
    Inventor: AstraZeneca AB
  • DPP-IV resistant GIP hybrid polypeptides with selectable properties
    Patent number: 8497240
    Abstract: The present invention relates generally to novel GIP analogs and GIP hybrid polypeptides with selectable properties, useful as agents for the treatment and prevention of metabolic diseases and disorders, for example those which can be alleviated by control plasma glucose levels, insulin levels, and/or insulin secretion, positive inotropic effects, reduction of catabolic effects, slowing of gastric emptying. Such conditions and disorders include, but are not limited to, hypertension, dyslipidemia, cardiovascular disease, eating disorders, critical care, insulin-resistance, obesity, and diabetes mellitus of any kind, including type 1, type 2, and gestational diabetes.
    Type: Grant
    Filed: August 17, 2007
    Date of Patent: July 30, 2013
    Assignees: Amylin Pharmaceuticals, LLC, AstraZeneca Pharmaceuticals LP
    Inventors: Odile Esther Levy, Alain D. Baron, Lawrence J. D'Souza, Mary Erickson, Soumitra S. Ghosh, Michael R. Hanley, Samuel Janssen, Carolyn M. Jodka, Diana Y. Lewis, Christine M. Mack, David G. Parkes, Richard A. Pittner, Christopher J. Soares, Ved Srivastava, Andrew A. Young, Thao Le
  • Quinazoline derivatives as angiogenesis inhibitors
    Patent number: 8492560
    Abstract: The invention relates to the use of compounds of formula (I) and salts thereof, in the manufacture of a medicament for use in the production of an antiangiogenic and/or vascular permeability reducing effect in warm-blooded animals, processes for the preparation of such compounds, pharmaceutical compositions containing a compound of formula I or a pharmaceutically acceptable salt thereof as active ingredient and compounds of formula I. The compounds of formula I and the pharmaceutically acceptable salts thereof inhibit the effects of VEGF, a property of value in the treatment of a number of disease states including cancer and rheumatoid arthritis.
    Type: Grant
    Filed: April 20, 2011
    Date of Patent: July 23, 2013
    Assignee: AstraZeneca AB
    Inventors: Elaine S E Stokes, Darren Mckerrecher, Laurent F A Hennequin, Patrick Ple
  • Elastic surgical ring clip/loader and a method
    Patent number: 8491607
    Abstract: Mounting apparatus for mounting an endless cord (2) which is expandable from a contracted condition to an expanded condition onto an end (1) of a structure having a transverse dimension greater than that of the cord when in the contracted condition comprising a tapered adaptor (14; 114) for the cord to be propelled over onto the end of the structure having a forward smaller end (16; to 116) for location in the cord in its contracted condition and a rear larger end (18; 118) for juxtaposing with the end of the structure and an expander device (24; 124; 224) movable relative to the adaptor to propel the cord over the adaptor onto the rear larger end thereof.
    Type: Grant
    Filed: July 12, 1999
    Date of Patent: July 23, 2013
    Assignee: AstraZeneca AB
    Inventors: Petri Horppu, Birger Amrén, Gudmund Dvärsäter
  • Amylin and Amylin Agonists for Treating Psychiatric Diseases and Disorders
    Publication number: 20130184213
    Abstract: Methods and compositions for treating psychiatric diseases and disorders are disclosed. The methods provided generally involve the administration of an amylin or an amylin agonist to a subject in order to treat psychiatric diseases and disorders, and conditions associated with psychiatric diseases and disorders.
    Type: Application
    Filed: February 26, 2013
    Publication date: July 18, 2013
    Applicants: Astrazeneca Pharmaceuticals LP, Amylin Pharmaceuticals, LLC
    Inventors: Kevin D. LAUGERO, Michael R. Hanley, Christine M. Mack, David G. Parkes, Andrew A. Young
  • Therapeutic Agents
    Publication number: 20130184250
    Abstract: Disclosed herein are azetidinyl compounds of formula I, as described herein, pharmaceutical compositions comprising an azetidinyl compound, and a method of using an azetidinyl compound in the treatment or prophylaxis of a melanin-concentrating hormone related disease or condition.
    Type: Application
    Filed: July 13, 2012
    Publication date: July 18, 2013
    Applicant: ASTRAZENECA AB
    Inventor: Lars Anders Mikael Johansson
  • GLP-1 RECEPTOR AGONIST COMPOUNDS HAVING STABILIZED REGIONS
    Publication number: 20130184203
    Abstract: The disclosure provides GLP-1 receptor agonist compounds having stabilized regions corresponding to alpha-helical regions of the natural peptide compounds. The disclosure also provides benzamide-containing exendin-4 analogs and alkene-constrained exendin-4 analogs, both of which have stabilized regions corresponding to alpha-helical regions of exendin-4.
    Type: Application
    Filed: July 27, 2011
    Publication date: July 18, 2013
    Applicants: AstraZeneca Pharmaceuticals LP, Amylin Pharmaceuticals, LLC
    Inventors: Josue Alfaro-Lopez, Abhinandini Sharma, Christopher J. Soares, Eugene Coats, Soumitra S. Ghosh
  • 9-(pyrazol-3-yl)-9H-purine-2-amine and 3-(pyrazol-3-yl) -3H-imidazo[4,5-B] pyridin-5-amine derivatives and their use for the treatment of cancer
    Patent number: 8486966
    Abstract: The present invention relates to compounds of Formula (I): and to their pharmaceutical compositions, and to their methods of use. These compounds provide a treatment for myeloproliferative disorders and cancer.
    Type: Grant
    Filed: May 2, 2008
    Date of Patent: July 16, 2013
    Assignee: Astrazeneca AB
    Inventors: Audrey Davies, Stephanos Ioannidis, Michelle Lamb, Mei Su, Tao Wang, Hai-Jun Zhang
  • Method of reducing plasma amylase and/or plasma lipase in patients with pancreatitis
    Patent number: 8481490
    Abstract: The disclosure provides the use of GLP-1 receptor agonist compounds to treat pancreatitis (e.g., acute, chronic, hemorrhagic, necrotizing) in patients. The disclosure also provides the use of GLP-1 receptor agonist compounds to reduce elevated plasma amylase and/or lipase concentrations in patients. An exemplary GLP-1 receptor agonist compound is exenatide.
    Type: Grant
    Filed: August 6, 2012
    Date of Patent: July 9, 2013
    Assignees: Amylin Pharmaceuticals, LLC, AstraZeneca Pharmaceuticals LP
    Inventors: Krystyna Tatarkiewicz, David G. Parkes, Denis Roy, Bronislava Gedulin
  • Device and method for deaggregating powder
    Patent number: 8479729
    Abstract: A device for inhalation of at least one air stream carrying a dose of medicament powder is provided. The device includes a flow passage passing a powder-containing cavity. A part of said flow passage propagates along a generally flat surface region. The flat surface region includes a cavity opening into said powder-containing cavity. The passing of an air stream along said flat surface region and outside said cavity generates an eddy in the cavity and the generated eddy contributes to deaggregation of the powder in said cavity and emptying of the powder from said cavity. Furthermore, a shear driven cavity principle is used in conjunction with such a device and a method of releasing medicament powder.
    Type: Grant
    Filed: December 18, 2008
    Date of Patent: July 9, 2013
    Assignee: AstraZeneca AB
    Inventors: Orest Lastow, Johan Remmelgas